Induction of primary, human antigen - Specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides

Journal of Immunotherapy

Volumn 21, Issue 1, 1998, Pages 32-40

  Wong, Christine ^a   Morse, Michael ^a   Nair, Smita K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigen presenting cells; Cytotoxic T lymphocytes; Dendritic cells; Proteasome inhibitors; TAP antisense oligonucleotides; Tumor vaccines

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MEMORY CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOEMBRYONIC ANTIGEN; CELL LINE; DENDRITIC CELLS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; HYBRID CELLS; LYMPHOCYTE ACTIVATION; OLIGONUCLEOTIDES, ANTISENSE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0031974234     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199801000-00004     Document Type: Article

References (40)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1981;9:271-96.
2. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1988;169:1255-64.
3. Nair S, Zhou F, Reddy R, Huang L, Rouse BT. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992; 175:609-12.
4. Nair S, Babu JS, Dunham RG, Kanda P, Burke RL, Rouse BT. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J Virol 1993;67:4062-9.
5. Rouse RJD, Nair SK, Lydy SL, Bowen JC, Rouse BT. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 1994;68:5685-9.
6. Macatonia SE, Patterson S, Knight SC. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 1991;74:399-406.
7. Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CDS+ CTLs from naive precursors. J Immunol 1994;153:996-1003.
8. Bakker ABH, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-4.
9. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
10. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-21.
11. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-26.
12. Boczkowski D, Nair S, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
13. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
14. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med 1996;183:317-22.
15. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky D. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
16. De Bruijn MLH, Schumacher TNM, Nieland JD, Ploegh HL, Kast WM, Melief CJM. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol 1991; 21:2963-70.
17. Franksson L, Petersson M, Kiessling R, Kärre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol 1993;23:2606-13.
18. Houbiers JGA, Nijman HW, van der Burg SJ, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23: 2072-7.
19. Langlade-Demoyen P, Levraud J-P, Kourilsky P, Abastado J-P. Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int Immunol 1994;6:1759-66.
20. 2-microglobulin observed in cells with increased sensitivity to NK cell lysis. J Immunol 1989;142:2911-7.
21. Attaya M, Jameson S, Martinez CK, et al. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature 1992;355: 647-9.
22. Yang Y, Früh K, Chambers J, Waters JB, Wu L, Spies T, Peterson PA. Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J Biol Chem 1992;267:11669-72.
23. DeMars R, Rudersdorf R, Chang C, et al. Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc Natl Acad Sci USA 1985;82:8183-7.
24. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-46.
25. Schumacher TNM, Heemels M-T, Neefjes JJ, Kast WM, Melief CJM, Ploegh HL. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990;62:563-7.
26. Nair SK, Snyder D, Gilboa E. Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. J Immunol 1996;156:1772-80.
27. Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997;27:589-97.
28. Rock KL, Cramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-71.
29. Yang B, Hahn YS, Hahn CS, Braciale TJ. The requirement for proteasome activity in class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Med 1996;183:1545-52.
30. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
31. Rammensee H-G, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11: 213-44.
32. Engelhard VH. Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 1994;6:13-23.
33. Shastri N. Needles in haystacks: identifying specific peptide antigens for T cells. Curr Opin Immunol 1996;8:271-7.
34. Zhou L-J, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995;154:3821-35.
35. Felgner J, Bennett F, Felgner PL. Cationic lipid-mediated delivery of polynucleotides. Methods Companion Methods Enzymol 1993; 5:67-75.
36. Volgmann T, Klein-Struckmeier A, Mohr H. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J Immunol Methods 1989;119:45-51.
37. Howard JC. Supply and transport of peptides presented by class I MHC molecules. Curr Opin Immunol 1995;7:69-76.
38. Jaeger J, Turner D, Zuker M. Improved predictions of secondary structures for RNA. Proc Natl Acad Sci USA 1989;86:7706-10.
39. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989;244:48-52.
40. Morse MA, Zhou L-J, Tedder TF, Lyerly K, Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann Surg 1997;226:6-16.